SEP 0226332Alternative Names: SEP 226332
Latest Information Update: 11 Jul 2007
At a glance
- Originator Sepracor
- Mechanism of Action Serotonin 3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 14 Jan 2004 Phase-I clinical trials in Sleep disorders in USA (unspecified route)